Analyst Price Targets — STAA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 14, 2026 11:21 am | Anthony Petrone | Mizuho Securities | $27.00 | $29.40 | TheFly | Staar Surgical price target raised to $27 from $22 at Mizuho |
| May 14, 2026 11:08 am | — | Canaccord Genuity | $32.00 | $29.40 | TheFly | Staar Surgical price target raised to $32 from $27 at Canaccord |
| May 14, 2026 11:02 am | — | Wedbush | $40.00 | $29.40 | TheFly | Staar Surgical upgraded to Outperform from Neutral at Wedbush |
| May 14, 2026 10:54 am | Adam Maeder | Piper Sandler | $33.00 | $29.40 | TheFly | Staar Surgical price target raised to $33 from $16 at Piper Sandler |
| May 14, 2026 10:41 am | Thomas Stephan | Stifel Nicolaus | $31.00 | $29.40 | TheFly | Staar Surgical price target raised to $31 from $18 at Stifel |
| April 9, 2026 8:53 am | — | Canaccord Genuity | $27.00 | $25.21 | TheFly | Staar Surgical upgraded to Buy from Hold at Canaccord |
| March 4, 2026 12:39 pm | — | Stifel Nicolaus | $18.00 | $19.22 | StreetInsider | STAAR Surgical (STAA) PT Lowered to $18 at Stifel After Noisy Q4 Results |
| February 9, 2026 11:57 am | — | Stifel Nicolaus | $19.00 | $17.58 | TheFly | Staar Surgical price target lowered to $19 from $28 at Stifel |
| February 3, 2026 1:00 pm | — | Wedbush | $26.00 | $18.16 | TheFly | Staar Surgical initiated with a Neutral at Wedbush |
| January 16, 2026 11:24 am | — | Morgan Stanley | $13.00 | $20.97 | TheFly | Staar Surgical resumed with an Underweight at Morgan Stanley |
Latest News for STAA
STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance, raising investor concerns. STAA demonstrated robust revenue growth, especially in China and the Americas, with improved margins and cost discipline, but EMEA sales lagged due to geopolitical issues. Despite recent profitability and a strong cash position, uncertainty remains over the…
STAAR Surgical Company (NASDAQ:STAA) stock is trading lower on Friday after reporting preliminary net sales for the second quarter of over $90 million, compared to net sales of $44.3 million a year ago.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced strong preliminary net sales for the second quarter ended July 3, 2026. STAAR is announcing its preliminary net sales in advance of its quarterly earnings announcement, which it expects to issue on August…
STAAR Surgical supplies implantable lenses for vision correction, serving ophthalmic surgeons and clinics globally with proprietary tech.
On May 28, 2026, Staar Surgical Co (STAA) shares fell 7.3% to a current price of $29.08. This decline comes amidst a volatile trading period, as the stock has e
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for STAA.
U.S. House Trading
No House trades found for STAA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.